These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25415150)

  • 1. Vascular healing and integration of a fully bioresorbable everolimus-eluting scaffold in a rabbit iliac arterial model.
    Vorpahl M; Nakano M; Perkins LE; Otsuka F; Jones R; Acampado E; Lane JP; Rapoza R; Kolodgie FD; Virmani R
    EuroIntervention; 2014 Nov; 10(7):833-41. PubMed ID: 25415150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography.
    Gomez-Lara J; Brugaletta S; Farooq V; Onuma Y; Diletti R; Windecker S; Thuesen L; McClean D; Koolen J; Whitbourn R; Dudek D; Smits PC; Chevalier B; Regar E; Veldhof S; Rapoza R; Ormiston JA; Garcia-Garcia HM; Serruys PW
    JACC Cardiovasc Interv; 2011 Dec; 4(12):1271-80. PubMed ID: 22192368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re-endothelialisation after Synergy stent and Absorb bioresorbable vascular scaffold implantation in acute myocardial infarction: COVER-AMI study.
    Lhermusier T; Ohayon P; Boudou N; Bouisset F; Campelo-Parada F; Roncalli J; Elbaz M; Carrié D
    Trials; 2019 Apr; 20(1):210. PubMed ID: 30975219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Evaluation of an Everolimus-Eluting Bioresorbable Vascular Scaffold Via a Long-Term Rabbit Iliac Artery Model.
    Park DS; Jeong MH; Jin YJ; Na MH; Sim DS; Kim M; Cho KH; Hyun DY; Oh S; Kim JH; Lim KS; Park JK; Kim HK; Hong YJ; Kim JH; Ahn Y; Kim JH
    Tissue Eng Regen Med; 2023 Apr; 20(2):239-249. PubMed ID: 36881249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular healing in drug-eluting stents: differential drug-associated response of limus-eluting stents in a preclinical model of stent implantation.
    Steigerwald K; Ballke S; Quee SC; Byrne RA; Vorpahl M; Vogeser M; Kolodgie F; Virmani R; Joner M
    EuroIntervention; 2012 Oct; 8(6):752-9. PubMed ID: 23086794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials.
    Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW;
    JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent.
    Onuma Y; Serruys PW; Gomez J; de Bruyne B; Dudek D; Thuesen L; Smits P; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia H; Ormiston JA;
    Catheter Cardiovasc Interv; 2011 Jul; 78(1):3-12. PubMed ID: 21413120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The absorb bioresorbable vascular scaffold in coronary bifurcations: insights from bench testing.
    Džavík V; Colombo A
    JACC Cardiovasc Interv; 2014 Jan; 7(1):81-8. PubMed ID: 24332424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials.
    Muramatsu T; Onuma Y; van Geuns RJ; Chevalier B; Patel TM; Seth A; Diletti R; García-García HM; Dorange CC; Veldhof S; Cheong WF; Ozaki Y; Whitbourn R; Bartorelli A; Stone GW; Abizaid A; Serruys PW; ; ; ; ; ;
    JACC Cardiovasc Interv; 2014 May; 7(5):482-93. PubMed ID: 24746650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lumen gain and restoration of pulsatility after implantation of a bioresorbable vascular scaffold in porcine coronary arteries.
    Lane JP; Perkins LE; Sheehy AJ; Pacheco EJ; Frie MP; Lambert BJ; Rapoza RJ; Virmani R
    JACC Cardiovasc Interv; 2014 Jun; 7(6):688-95. PubMed ID: 24835327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial.
    Gogas BD; Serruys PW; Diletti R; Farooq V; Brugaletta S; Radu MD; Heo JH; Onuma Y; van Geuns RJ; Regar E; De Bruyne B; Chevalier B; Thuesen L; Smits PC; Dudek D; Koolen J; Windecker S; Whitbourn R; Miquel-Hebert K; Dorange C; Rapoza R; Garcia-Garcia HM; McClean D; Ormiston JA
    JACC Cardiovasc Interv; 2012 Jun; 5(6):656-65. PubMed ID: 22721662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population.
    Costopoulos C; Latib A; Naganuma T; Miyazaki T; Sato K; Figini F; Sticchi A; Carlino M; Chieffo A; Montorfano M; Colombo A
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):E10-5. PubMed ID: 24909303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
    Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
    JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE V stent in a porcine coronary artery model.
    Otsuka F; Pacheco E; Perkins LE; Lane JP; Wang Q; Kamberi M; Frie M; Wang J; Sakakura K; Yahagi K; Ladich E; Rapoza RJ; Kolodgie FD; Virmani R
    Circ Cardiovasc Interv; 2014 Jun; 7(3):330-42. PubMed ID: 24895447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.
    Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B
    Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents.
    Gomez-Lara J; Garcia-Garcia HM; Onuma Y; Garg S; Regar E; De Bruyne B; Windecker S; McClean D; Thuesen L; Dudek D; Koolen J; Whitbourn R; Smits PC; Chevalier B; Dorange C; Veldhof S; Morel MA; de Vries T; Ormiston JA; Serruys PW
    JACC Cardiovasc Interv; 2010 Nov; 3(11):1190-8. PubMed ID: 21087756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds.
    Gomez-Lara J; Brugaletta S; Diletti R; Garg S; Onuma Y; Gogas BD; van Geuns RJ; Dorange C; Veldhof S; Rapoza R; Whitbourn R; Windecker S; Garcia-Garcia HM; Regar E; Serruys PW
    Eur Heart J; 2011 Feb; 32(3):294-304. PubMed ID: 21123276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasomotor function and re-endothelialisation after implantation of biodegradable abluminal polymer coated paclitaxel-eluting stents in rabbit iliac arteries: a time-course study.
    Nakamura T; Winsor-Hines D; Yin X; Sushkova N; Chen JP; King SB; Chronos N; Eppihimer M; Huibregtse B; Dawkins KD; Hou D
    EuroIntervention; 2012 Aug; 8(4):493-500. PubMed ID: 22917733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials.
    Gogas BD; Bourantas CV; Garcia-Garcia HM; Onuma Y; Muramatsu T; Farooq V; Diletti R; van Geuns RJ; De Bruyne B; Chevalier B; Thuesen L; Smits PC; Dudek D; Koolen J; Windecker S; Whitbourn R; McClean D; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Ormiston JA; Serruys PW
    EuroIntervention; 2013 Oct; 9(6):709-20. PubMed ID: 23628499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.